This position will have the opportunity to work directly on novel antibody-drug conjugates in hematologic malignancies and/or solid tumors. Within Clinical Development Operations, the candidate will function as a scientific and medical resource within the department and as a clinical scientist fellow for ongoing clinical trials in oncology.
The fellow will have the opportunity to provide support across Seagen’s broad portfolio, including late stage agents such as ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), and TUKYSA® (tucatinib), as well as the early stage pipeline.
Contribute to the execution of clinical trials through work within the Clinical Trial Management, Clinical Project Management, and Clinical Research teams.
Participate in the development of clinical protocols and amendments, investigator brochures, and clinical study reports
Aid in the strategic development of early and late stage clinical programs
Contribute to clinical study teams and provide appropriate scientific oversight for ongoing clinical studies
Evaluate safety, pharmacology, and efficacy data from ongoing and completed studies
Prepare presentations for Investigator Meetings, Advisory Boards, and Steering Committee Meetings
Conduct literature reviews and prepare summaries to support clinical development programs
Serve as the scientific and medical resource for the design and interpretation of clinical and preclinical data to support existing and new development candidates
We are looking for someone who:
Demonstrates a passion for helping patients with cancer and for the science of oncology drug development
Has a strong leadership presence with an ability to work effectively with other clinical and scientific leaders
Is able to collaborate with internal company leadership, external development partners, and investigators/medical professionals
Has a global perspective and mindset, with the ability to work effectively with colleagues from a myriad of cultures, backgrounds, and geographies
Clinical oncology experience: 1-2 years of industry experience in oncology drug development preferred
Seagen is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Wednesday, November 25th. Please include include the following with your application:
Letter of intent
3 Professional References (phone number and email) upon formal request
Employer will assist with relocation costs.
Internal Number: 2020-764
Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.
As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies to deliver cell-killing agents directly to cancer cells. This technology is the foundation of two of our approved medicines—ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv).
Today, our research efforts are focused on advancing a pipeline of novel targeted therapies, including TUKYSA® (tucatinib), recently approved for certain metastatic HER2+ breast cancers. We’re also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.